RT Journal Article
SR Electronic
A1 Buckley, Rita
T1 No Increased CV Events with DPP-4 Inhibitors
JF MD Conference Express
YR 2011
FD SAGE Publications
VO 11
IS 11
SP 11
OP 11
DO 10.1177/155989771111004
UL http://mdc.sagepub.com/content/11/11/11.1.abstract
AB A new meta-analysis suggests that dipeptidyl peptidase-4 (DPP-4) inhibitors are associated with a reduced risk of major cardiovascular events compared with placebo or other treatment, irrespective of trial duration, type of DPP-4 inhibitor, or comparator.